Juvabis

AMR Stakeholder Profile​

Juvabis

juvabis

Focus area/active in: Human Health | Therapeutics

Company/Organisation type: SME

About:
Juvabis is a clinical-stage Swiss biopharmaceutical start-up that addresses the global challenge of life-threatening bacterial infections by designing and developing next-generation aminoglycoside-antibiotics. Juvabis aims to treat antibiotic-resistant infections with aminoglycoside-therapies of unprecedented safety and efficacy. Juvabis’ best-in-class clinical-candidate apramycin is currently in Phase 1 first-in-human trials, being developed in partnership with the Innovative Medicines Initiative. 

Website: www.juvabis.com

Partnering

Would you like to meet Juvabis virtually during the AMR Conference week?

Get in touch!

Marc Creus
Head of Business Development
Juvabis AG

Please fill out the form below to get in touch with us.

Share this page:

Share on twitter
Twitter
Share on linkedin
LinkedIn